Core Viewpoint - Chongqing Huasen Pharmaceutical Co., Ltd. announced that its subsidiary, Huasen Inno Biotech Co., Ltd., has received the Clinical Trial Approval Notification for the innovative drug HSN002066C1 from the National Medical Products Administration, marking a significant milestone in the company's drug development efforts [1]. Group 1: Drug Approval Details - Huasen Inno has been granted approval for HSN002066C1, a selective small molecule inhibitor of PARP7, intended for oral administration in the treatment of advanced malignant solid tumors [1]. - The drug has shown high exposure levels in mice and significant tumor suppression activity in various tumor models, either as a monotherapy or in combination therapy [1]. Group 2: Impact on the Company - HSN002066C1 is the first Class 1 innovative drug project approved for clinical trials by Huasen Inno, establishing a solid foundation for the company's strategy of combining innovation and generics [1]. - The company acknowledges that the drug development process is subject to various uncertainties, including technical, regulatory, and market competition factors, which may affect the clinical trial progress and the eventual market approval [1].

Group 1 - The company Huason Pharmaceutical announced that its subsidiary, Chongqing Huason Inno Biotech Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of HSN002066C1 tablets in two specifications [1] - This approval marks a significant step in the company's research and development efforts in the pharmaceutical sector [1] - The clinical trial approval is expected to enhance the company's product pipeline and potentially lead to new market opportunities [1]

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Inno Biotech Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HSN002066C1 tablets, marking a significant milestone for the company's innovative drug development [1]. Group 1 - HSN002066C1 tablets are the first Class 1 innovative drug project approved for clinical trials by Huason Inno, highlighting the company's commitment to innovation in drug development [1]. - The approval is expected to lay a solid foundation for the company's strategy of combining innovation and generics in its development approach [1].

Group 1 - Hengyu Environmental reported a revenue of 294 million yuan for 2025, an increase of 89.87%, and a net profit of 35.93 million yuan, up 106.25% year-on-year [1] - Yongxi Electronics achieved a revenue of 4.4 billion yuan in 2025, a growth of 21.92%, with a net profit of 82.24 million yuan, reflecting a year-on-year increase of 23.99% [2] - Zhongwei Semiconductor reported a revenue of 1.122 billion yuan for 2025, a 23.09% increase, and a net profit of 285 million yuan, up 108.05% year-on-year [3] - Sry New Materials achieved a revenue of 1.564 billion yuan in 2025, a growth of 17.66%, with a net profit of 154 million yuan, reflecting a year-on-year increase of 35.04% [14] - Jiaokong Technology reported a revenue of 2.537 billion yuan for 2025, a growth of 16.08%, and a net profit of 156 million yuan, up 86.13% year-on-year [15] - SanSheng Guojian reported a revenue of 4.199 billion yuan for 2025, a significant increase of 251.81%, with a net profit of 2.939 billion yuan, up 317.09% year-on-year [30] Group 2 - Aidi Pharmaceutical reported a revenue of 721 million yuan for 2025, a growth of 72.49%, but incurred a net loss of 19.73 million yuan, reducing losses from 142 million yuan in the previous year [5] - Weidao Nano reported a revenue of 2.632 billion yuan for 2025, a decrease of 2.52%, with a net profit of 213 million yuan, down 6.12% year-on-year [9] - Wens Foodstuff Group reported a revenue of 103.884 billion yuan for 2025, a decline of 1.67%, with a net profit of 5.235 billion yuan, down 43.59% year-on-year [29] - Supor reported a revenue of 22.772 billion yuan for 2025, a growth of 1.54%, with a net profit of 2.097 billion yuan, down 6.58% year-on-year [33] Group 3 - ShaoNeng Co. signed a significant operational contract worth 22 million yuan for a biomass power generation project [6] - Shunlian Bio plans to use 237 million yuan to acquire controlling interest in a joint venture, increasing its stake from 16.99% to 51% [7] - Huason Pharmaceutical's subsidiary received clinical trial approval for an innovative drug, indicating progress in its product pipeline [8] - Xinyang Technology's subsidiary received a medical device registration certificate, enhancing its product offerings [10][11] - Yida Co. obtained an investment project filing certificate for a chemical production project with a total investment of 642 million yuan [12]

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, marking a significant milestone in the company's innovative drug development strategy [1] Group 1: Product Development - HSN002066C1 tablets, a selective PARP7 small molecule inhibitor, are developed independently by Huason Yino and possess complete intellectual property rights [1] - The drug is intended for oral administration in the treatment of advanced malignant solid tumors, demonstrating significant tumor suppression activity in various tumor models [1] - HSN002066C1 is the first Class 1 innovative drug project approved for clinical trials by Huason Yino, establishing a solid foundation for the company's strategy of combining innovation and generics [1]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) announced that its subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd. (referred to as "Huason Yino"), has received the Clinical Trial Approval Notice from the National Medical Products Administration for the HSN002066C1 tablet in two specifications [1] Group 1 - HSN002066C1 tablet (with free base HSN002B015) is a selective small molecule inhibitor of poly(ADP-ribose) polymerase 7 (PARP7) developed independently by Huason Yino, with full ownership of intellectual property rights [1] - The clinical application of HSN002066C1 is intended for the treatment of patients with advanced malignant solid tumors [1] - HSN002066C1 is characterized as a potent and highly selective PARP7 inhibitor, showing significant tumor suppression activity in various tumor models when administered alone or in combination [1]

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Inno Biotech Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, a selective PARP7 inhibitor for treating advanced malignant solid tumors [1] Group 1 - HSN002066C1 tablets, with the free base HSN002B015, are independently developed by Huason Inno and fully owned in terms of intellectual property rights [1] - The drug is intended for oral administration and has shown significant tumor suppression activity in various tumor models when used alone or in combination [1] - HSN002066C1 is characterized as a potent and highly selective PARP7 inhibitor, demonstrating high exposure levels in mice [1]

二、药品研发及相关情况 证券代码：002907 证券简称：华森制药 公告编号：2026-007 重庆华森制药股份有限公司 关于子公司获得创新药《药物临床试验批准通知书》 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）子公司重庆华森英诺生物 科技有限公司（以下简称"华森英诺"）于近日收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的 HSN002066C1 片两个规格的《药物临床试验批 准通知书》。现将相关情况公告如下： 一、药物临床试验批准通知书的主要内容 | 药 | 物 | 名 | 称：HSN002066C1 片 | | --- | --- | --- | --- | | 受 | | 理 | 号：CXHL2501398;CXHL2501399 | | 注 | 册 | 分 | 类：1.1 类新药 | | 适 | | 应 | 症：晚期恶性实体瘤 | | 申 | | 请 | 人：重庆华森英诺生物科技有限公司 | | 审 | 批 | 结 | 论：根据《中华人民共和国药品管理法》及有关规定， | | | ...

Core Viewpoint - Huason Pharmaceutical announced that HSN002066C1 tablets have received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing clinical trials for advanced malignant solid tumors [1] Group 1 - The drug HSN002066C1 is classified as a Class 1.1 new drug [1] - The application numbers for the approval are CXHL2501398 and CXHL2501399 [1] - The indication for HSN002066C1 is for advanced malignant solid tumors, and it is approved for monotherapy in clinical trials [1]

Group 1: Company Announcements - Changfei Fiber currently does not engage in CPO-related business [1] - GCL-Poly Energy lacks production capacity for "space photovoltaic" products [1] - Zhongke High-tech plans to invest 145 million yuan in a new PCB drill pin project with an annual capacity of 30 million units [1] - Samsung Medical's wholly-owned subsidiary is expected to win a bid for a 321 million yuan project from Southern Power Grid [1] - Solar Energy's subsidiary intends to acquire 100% equity of Jinhua Windling [1] - SMIC expects a net profit of 1.223 billion yuan for Q4 2025, a year-on-year increase of 23.2% [2] - Kying Network has conducted its first buyback of 2.061 million shares [1] - Runbei Aerospace's controlling shareholder plans to reduce its stake by up to 3% [1] - Zhen'an Technology plans to raise no more than 740 million yuan through a private placement [1] - Jiangsu New Energy intends to issue convertible bonds to raise no more than 1.24 billion yuan [1] Group 2: Investment Projects - Kangda New Materials' subsidiary plans to invest in a project with an annual output of 30,000 tons of polyarylether [1] - China Shipbuilding Industry Corporation plans to build a comprehensive materials park [1] - Dong'a Ejiao intends to invest 1.485 billion yuan in a health consumer goods industrial park [1] - Hongda Co., Ltd. plans to invest approximately 71.43 million yuan in a 110kV power transmission and transformation project [1] Group 3: Share Buybacks and Reductions - Kying Network has executed its first buyback of 2.061 million shares [3] - Huasen Pharmaceutical's Liu Xiaoying plans to reduce her stake by up to 3% [3] - Wushang Group's Dazi Yintai plans to reduce its stake by up to 3% [3] - Runbei Aerospace's controlling shareholder plans to reduce its stake by up to 3% [3]